JAMA Oncology

出版年份:暂无数据 年文章数:1010 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:1.9% 审稿周期: 开通期刊会员,数据随心看



2023年中国人文章占该期刊总数量暂无数据 (2022年为100.00%)
1.9 %
点击查看 (点击次数:9348)
点击查看 (点击次数:6812次)
点击查看 (点击次数:6573次)

Vision. JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.

Mission. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers.JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

Editorial Team. The founding Editor in Chief of JAMA Oncology is Mary L. (Nora) Disis, MD. Dr Disis is a Professor of Medicine and Adjunct Professor of Pathology and Obstetrics and Gynecology at the University of Washington (UW), and a Member of the Fred Hutchinson Cancer Research Center. She is the Associate Dean for Translational Science in the UW School of Medicine, Director of the UW Center for Translational Medicine and Women''''''''s Health, and Director, UW Institute for Translational Health Sciences. Dr Disis is an expert in breast and ovarian cancer, immunotherapy, and translational research. For a complete listing of the journal’s Editors and Editorial Board, see link to Editors and Publishers below.

Journal Publication and Editorial Information. JAMA Oncology is an international peer-reviewed journal that is published online each Thursday and in a print/online issue every month. The acceptance rate is 21%. Time to initial editorial decision is 1 day without review and 35 days with review. All articles are published Online First within a median of 71 days of acceptance. All research articles are made free access online 12 months after publication. All articles are made free access on The JAMA Network Reader on the day of publication. JAMA Oncology also has an open access option for authors of eligible manuscripts. See Instructions for Authors for details. In addition, the journal is made freely available or nearly so to institutions in developing countries through the World Health Organizations HINARI program.


Topics of Interest. JAMA Oncology publishes papers on all aspects medical, radiation, and surgical oncology and its subspecialties, including the following Topics:

  • Breast Cancer
  • Cancer Biomarkers
  • Cancer Genetics
  • Cancer-Related Complications
  • Cancer Therapy and Treatment
  • Bone Marrow/Stem Cell Transplantation
  • Chemotherapy
  • Novel Therapies
  • Treatment-Related Complications
  • Clinical Guidelines
  • Clinical Trials
  • Diagnosis and Staging
  • Drug Discovery
  • Endocrine System Cancer
  • Epidemiology, Cancer Prevention, and Control
  • Gastrointestinal Cancer
  • Biliary Cancer
  • Colon Cancer
  • Esophageal Cancer
  • Gastric Cancer
  • Hepatic Cancer
  • Pancreatic Cancer
  • Rectal Cancer
  • Genitourinary Cancer
  • Prostate Cancer
  • Renal Cancer
  • Urinary Tract Cancer
  • Geriatric Oncology
  • Gynecologic Cancer
  • Cervical Cancer
  • Endometrial Cancer
  • Ovarian Cancer
  • Head & Neck Cancer
  • Hematologic Malignancies
  • Imaging
  • Immunotherapy
  • Lung Cancer
  • Neuro-oncology
  • Brain Cancer
  • Central Nervous System Cancer
  • Palliative Care
  • Cancer Supportive Care
  • Pain Control
  • Pediatric Cancer
  • Quality and Health Services Research
  • Economics
  • Health Policy
  • Radiation Oncology
  • Sarcomas
  • Skin Cancer
  • Melanoma
  • Soft-Tissue Tumors
  • Translational Oncology
  • Unknown Primary Site and Rare Cancers

JAMA Oncology
ISSN 2374-2437 (Print)
ISSN 2374-2445 (Online)


Updated April 2016